Related Experiment Video

Updated: Jul 9, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon

Jian Ming Fan1, Qiao Zhang, Jun Xu

  • 1The Laboratory of Toxicology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China. 5746067@sohu.com

Molecular Biology Reports
|December 7, 2007
PubMed

Insights

Bitter melon

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Hepatology

Background:

  • Hepatitis B virus (HBV) infection is a global health concern.
  • Current treatments for HBV are limited in efficacy and can have side effects.
  • Novel therapeutic agents targeting HBV replication are needed.

Purpose of the Study:

  • To investigate the anti-HBV activity of MAP30 protein from bitter melon.
  • To evaluate the dose- and time-dependent effects of MAP30 on HBV replication and markers.

Main Methods:

  • Recombinant MAP30 protein was expressed and purified.
  • Hepatoma G2.2.15 cells were treated with MAP30.
  • MTT assay for cytotoxicity, real-time PCR and Southern hybridization for HBV DNA quantification.
  • ELISA for HBsAg and HBeAg assessment.

Main Results:

  • MAP30 significantly inhibited HBV DNA replication, HBsAg, and HBeAg secretion in a dose- and time-dependent manner.
  • Lower doses of MAP30 (8.0 microg/ml) effectively reduced HBsAg and HBeAg expression.
  • Statistical significance (P < 0.05) was observed for inhibition rates.

Conclusions:

  • MAP30 exhibits potent anti-HBV activity.
  • MAP30 is a promising candidate for the development of new hepatitis B therapies.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...